Update of Food-Cobalamin Malabsorption and Oral Cobalamin Therapy

Emmanuel Andrès¹,* , Josep Vidal-Alaball², Laure Federici¹, Oliver Lidove³, Jacques Zimmer⁴ and Georges Kaltenbach⁵

¹Department of Internal Medicine, Diabetes and Metabolic Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; ²Department of General Practice, Cardiff University, UK; ³Department of Internal Medicine, Groupe Hospitalier Bichat-Claude Bernard, Paris, France; ⁴Laboratoire d’Immunogénétique-Allergologie, Centre de Recherche Public de la Santé (CRP-Santé) de Luxembourg, Luxembourg and ⁵Department of Internal Medicine and Geriatrics, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Abstract: Cobalamin (vitamin B12) deficiency is particularly common in the elderly (>65 years of age), but is often unrecognized because its clinical manifestations are subtle; however, they are also potentially serious, particularly from a neuropsychiatric and hematological perspectives. In the general population, the main causes of cobalamin deficiency are pernicious anemia and food-cobalamin malabsorption. Food-cobalamin malabsorption syndrome, which has only recently been identified, is a disorder characterized by the inability to release cobalamin from food or its binding proteins. This syndrome is usually caused by atrophic gastritis, related or unrelated to *Helicobacter pylori* infection, and long-term ingestion of antacids and biguanides. Management of cobalamin deficiency with cobalamin injections is currently well codified, but new routes of cobalamin administration (oral and nasal) are being studied, especially oral cobalamin therapy for food-cobalamin malabsorption.

Key Words: Cobalamin, vitamin B12, cobalamin deficiency, food-cobalamin malabsorption, oral cobalamin therapy.

INTRODUCTION

Cobalamin or vitamin B12 deficiency is common in elderly patients [1], but is often unrecognized or uninvestigated because the clinical manifestations of cobalamin deficiency are subtle. However, the complications of cobalamin deficiency, particularly the neuropsychiatric and hematological [1-4], are potentially serious and therefore require investigation in all patients present with vitamin or nutritional deficiency. Classic disorders, such as pernicious anemia, are the causes of cobalamin deficiency in only a limited number of patients, especially elderly patients [4]. A more common problem is food-cobalamin malabsorption, a disorder characterized by the inability to release vitamin B12 from food or its binding proteins [4]. Since the description of this later disorder, several authors have demonstrated that oral cobalamin therapy which can be a pharmacotherapeutic option for the treatment of cobalamin deficiency [4]. This review summarizes the current knowledge on cobalamin deficiency, with a particular focus on food-cobalamin malabsorption and oral cobalamin therapy.

DEFINITION OF COBALAMIN DEFICIENCY

Literature of the last ten years has provided several definitions of cobalamin deficiency, depending mainly on the population studied and on the particular assay kits used [5-7]. Varying test sensitivities and specificities result from the lack of a precise ‘gold standard’ for the diagnosis of cobalamin deficiency, especially in elderly patients. The definitions of cobalamin deficiency used in this review are shown in Box 1 [7,8]. At present, cobalamin deficiency is often defined in terms of the value of serum cobalamin (<150 pmol/l or <200 pg/ml) and of homocysteine (>13 μmol/l) and methyl malonic acid (>0.4 μmol/l), two components of the cobalamin metabolic pathway. It is important to note that only methyl malonic acid is specific for the cobalamin deficiency. Increased homocysteine is also caused by folate and vitamin B6 deficiency. In the future, new serum cobalamin assay kits such as holotranscobalamin may replace older assay kits and become the standard for testing for cobalamin deficiency [9]. However, to date, little and conflicting evidence is available about the effectiveness of these new tests in real life clinical practice.

EPIDEMIOLOGY OF COBALAMIN DEFICIENCY

Epidemiological studies show that in the general population of industrialized countries cobalamin deficiency has a prevalence of around 20%, ranging from 5% to 60% depending the definition of cobalamin deficiency used [4,9]. The Framingham study demonstrated a prevalence of 12% among elderly people living in the community [10]. Other studies focusing on elderly people, particularly those who are in institutions or who are sick and malnourished, have suggested a higher prevalence of 30–40% [11,12]. Using stringent definition, we found that cobalamin deficiency had a prevalence of 5% in a group of patients followed or hospitalized in a tertiary reference hospital [8].
**COBALAMIN METABOLISM AND FUNCTION**

The different stages of cobalamin metabolism and corresponding causes of cobalamin deficiency are shown in Table 1 [4,13-15]. Absorption depends mainly on intrinsic factor, which is secreted by the gastric mucosa. Intrinsic factor binds cobalamin forming a complex that is absorbed by the terminal ileum. This mechanism is responsible for at least 60% absorption on oral cobalamin [13-15]. Cobalamin metabolism is complex and requires many processes, any one of which, if not present, may lead to cobalamin deficiency [4,13-15]. Once metabolized, cobalamin is a cofactor and coenzyme in many biochemical reactions, including DNA synthesis, methionine synthesis from homocysteine and conversion of propionyl into succinyl coenzyme A from methylmalonate [4,8,9]. A typical Western diet contributes 3–30 μg of cobalamin per day towards the recommended dietary allowance set by the Food and Nutrition Board of the Institute of Medicine (US) of 2.4 g/day for adults and 2.6 to 2.8 g/day during pregnancy [16]. It has been estimated that there is a delay of 5 to 10 years between the onset of cobalamin deficiency and the development of clinical illness, this is a direct result of the hepatic stores (>1.5 mg) and the enterohepatic cycle [4,13]. Of particular interest is the observation that between 1% to 5% of free cobalamin (or crystalline cobalamin) is absorbed along the entire intestine by passive diffusion. This absorption explains the mechanism underlying oral cobalamin oral treatment of cobalamin deficiencies [17,18].

**CLASSICAL CAUSES OF COBALAMIN DEFICIENCY**

Fig. (1) presents the principal causes of cobalamin deficiency in 172 elderly patients (median age: 70 years) hospitalized in the university hospital of Strasbourg, France [14]. In elderly patients, cobalamin deficiency is classically caused by pernicious anemia or Biermer’s or Addison’s disease [1,11]. The principal characteristics of pernicious anemia have been reported in detail in several reviews [19-21]. Cobalamin deficiency caused by dietary deficiency or malabsorption is rarer. Dietary causes of deficiency are limited to elderly people who are already malnourished, such as elderly patients living in institutions (they may consume inadequate amounts of vitamin B12-containing foods) or in psychiatric hospitals (strict vegetarian) [4,13]. Since the 1980s, the malabsorption of cobalamin has become rarer, owing mainly to the decreasing frequency of gastrectomy and surgical resection of the terminal small intestine [4,8,14]. Several disorders commonly seen in gastroenterology practice might, however, be associated with cobalamin malabsorption. These include deficiency in the exocrine function of the pancreas after chronic pancreatitis (usually alcoholic), lymphomas or tuberculosis (of the intestine),

**Table 1. Stages of Cobalamin Metabolism and Corresponding Causes of Cobalamin Deficiency [13,15]**

| Stages and Actors in Cobalamin Metabolism | Causes of Cobalamin Deficiency |
|------------------------------------------|--------------------------------|
| Intake solely through food               | – Strict vegetarianism (patients who are sick in institutions or in psychiatric hospitals) |
| Digestion brings into play:             | – Gastrectomies |
|   – Haptocorrin                          | – Pernicious anemia |
|   – Gastric secretions (hydrochloric acid and peptic) | – Food-cobalamin malabsorption |
|   – Intrinsic factor                     | – Ileal resections and malabsorption |
|   – Pancreatic and biliary secretions    | – Pernicious anemia |
|   – Enterohepatic cycle                  | – Food-cobalamin malabsorption |
| Absorption brings into play:            | – Congenital deficiency in transcobalamin II |
|   – Intrinsic factor                     | – Congenital deficiency in various intracellular enzymes |
|   – Cubilin, amionless                   | – Calcium and energy |
| Transport by transcobalamin              | – Intracellular metabolism based on various intracellular enzymes |
Crohn’s disease, Whipple’s disease, and uncommonly celiac disease [11,15]. Food-cobalamin malabsorption has been found to be the leading cause of cobalamin malabsorption, especially in elderly patients [4,8,11,22]. In our studies [14,23], in which we have now followed more than 300 patients with a documented cobalamin deficiency, food-cobalamin malabsorption accounts for about 60–70% of the cases of cobalamin deficiency in elderly patients, whereas pernicious anemia accounted for only 15–25%.

**FOOD-COBALAMIN MALABSORPTION**

First described by Carmel in 1995 [22], food-cobalamin malabsorption is a syndrome characterized by the inability of the body to release cobalamin from food or intestinal transport proteins, particularly in the presence of hypochlorhydria, where the absorption of “unbound” cobalamin is normal (“maldigestion”). In our experience, this syndrome accounted for 60 to 70% of cases of cobalamin deficiency in elderly patients [14,15]. This syndrome is characterized by cobalamin deficiency in the presence of sufficient food-cobalamin intake and a normal Schilling test ruling out malabsorption or pernicious anemia (diagnostic of exclusion) [14,22,23]. Thus in this syndrome, patients can absorb “unbound” cobalamin through intrinsic factor or passive diffusion mechanisms. Thus the recognition of the syndrome permits new developments of oral cobalamin therapy [4]. The principal characteristics of this syndrome are listed in Table 2. Authors supporting the existence of this syndrome have employed a modified Schilling test, which uses radioactive cobalamin bound to animal proteins (e.g., salmon, trout) and reveals malabsorption when the results of a standard Schilling test are normal [4,14,23].

Some authors have speculated about the reality and significance of cobalamin deficiency related to food-cobalamin malabsorption [4], because many patients have only mild clinical or hematological features. However, several of the patients we have described in a recently published study [14] had serious features classically associated with pernicious anemia, including polyneuropathy, confusion, dementia, medullar-combined sclerosis, anemia and pancytopenia. Nevertheless, the partial nature of this form of malabsorption may produce a more slowly progressive depletion of cobalamin than does the more complete malabsorption engendered by disruption of the intrinsic factor-mediated absorption. The slower progression of depletion probably explains why mild, preclinical deficiency is more frequently associated with food-cobalamin malabsorption than with pernicious anemia [4,14].

### Table 2. Food-Cobalamin Malabsorption Syndrome [4,14,15]

| Criteria for Food-Cobalamin Malabsorption | Associated Conditions or Agents |
|-----------------------------------------|--------------------------------|
| Low serum cobalamin (vitamin B12) levels| Gastric disease: atrophic gastritis, type A atrophic gastritis, gastric disease associated with *Helicobacter pylori* infection, partial gastrectomy, gastric by-pass, vagotomy |
| Normal results of Schilling test using free cyanocobalamin labeled with cobalt-58 or abnormal results of derived Schilling test ‡| Pancreatic insufficiency: alcohol abuse |
| No anti-intrinsic factor antibodies| Gastric or intestinal bacterial overgrowth: achlorhydria, tropical sprue, Ogilvie’s syndrome, HIV |
| No dietary cobalamin deficiency| Drugs: antacids (H2-receptor antagonists and proton pump inhibitors) or biguanides (metformin) |

‡ Derived Schilling tests use food-bound cobalamin (e.g., egg yolk, chicken and fish proteins).
Food-cobalamin malabsorption is caused primarily by atrophic gastritis [14]. Over 40% of patients older than 80 years of age have gastric atrophy that might or might not be related to Helicobacter pylori infection [11,24]. Other factors that contribute to food-cobalamin malabsorption in elderly people include chronic carriage of H. pylori and intestinal microbial proliferation (in which case cobalamin deficiency can be corrected by antibiotic treatment) [24,25]; long-term ingestion of antacids, including H₂-receptor antagonists and proton-pump inhibitors [26,27], particularly among patients with Zollinger-Ellison syndrome [28,29], and biguanides (metformin) [30-32]; chronic alcoholism; surgery or gastric reconstruction (e.g. bypass surgery for obesity); partial pancreatic exocrine failure [4,14], and Sjögren’s syndrome or systemic sclerosis [33] (Table 2). In a series of 92 elderly patients (mean age: 76 years) with food-cobalamin malabsorption [14], we have reported at least one of these associated conditions or agents in 60% of the patients. These conditions mainly include atrophic gastritis (± H. pylori infection) in 30% of the patients and long-term metformin or antacid intake in 20% of the elderly patients.

**CLINICAL MANIFESTATIONS OF COBALAMIN DEFICIENCY**

The clinical manifestations are highly polymorphic and of varying severity, ranging from milder conditions such as tiredness, common sensory neuropathy, atrophic glossitis (Hunter’s glossitis) and isolated anomalies of macrocytosis or hypersegmentation of neutrophils, to severe disorders, including combined sclerosis of the spinal cord, hemolytic anemia and even pancytopenia [2,14,34-36]. Frequently, neurologic signs and symptoms precede hematologic abnormalities or continue to be isolated. Several new studied or established manifestations of cobalamin deficiency are described in Table 3. In the aforementioned series of 92 patients with food-cobalamin malabsorption [14], we have found at least one clinical feature and hematological abnormalities, 70% and 76% of the patients respectively. Cobalamin deficiency appears to be more common among patients who have a variety of chronic neurologic conditions such as dementia, Alzheimer’s disease, stroke, Parkinson’s disease and depression, although it is unclear if these are causal relationships [4,37]. In our own studies in which we administered cobalamin to patients with dementia, improvement was not observed [8,14]. Other studies have had similar results [18,38]. At this time a causal role of cobalamin in these conditions remains speculative.

**CLASSICAL TREATMENT OF COBALAMIN DEFICIENCY**

The classic treatment for cobalamin deficiency, particularly when the cause is not dietary deficiency, is parenteral administration—usually by intramuscular injection—of this vitamin (in the form of cyanocobalamin and, more rarely, hydroxocobalamin) [1,17,18,34]. In France, the recommended practice is to build up the tissue stores of the vitamin quickly and correct serum cobalamin hypovitaminosis, particularly in the case of pernicious anemia. The treatment involves the administration of 1,000 μg of cyanocobalamin per day for 1 week, followed by 1,000 μg per week for 1 month, followed by 1,000 μg per month, normally for the rest of the patient’s life [8,11,19]. In USA and UK, dosages ranging from 100 to 1,000 μg per month (or every 2-3 months when hydroxocobalamin is given) are used during the rest of the patient’s life [4,17].

**ORAL COBALAMIN THERAPY**

In cases of cobalamin deficiency other than those caused by nutritional deficiency, alternative routes of cobalamin administration have been used: oral [17,18,39-45] and nasal [46,47]. These other routes of administration have been proposed as a way of avoiding the discomfort, inconvenience and cost of monthly injections. Our working group has developed an effective oral treatment of food-cobalamin deficiency involving the administration of 1,000 μg of cyanocobalamin per week for 1 month, followed by 1,000 μg per month, normally for the rest of the patient’s life [4,17].

| Table 3. Main Clinical Features of Cobalamin Deficiency [2,4,14,15,34-36] |
|---------------------------------------------------------------|
| **Hematological Manifestations**                      | **Neuro-Psychiatric Manifestations**                   | **Digestive Manifestations**                          | **Other Manifestations**                    |
| Frequent: macrocytosis, neutrophil hypersegmentation, aregenerative macrocytary anemia, medullar megaloblastosis (“blue spinal cord”) | Frequent: polyneuritis (especially sensitive), ataxia, Babinski’s phenomenon | Classic: Hunter’s glossitis, jaundice, LDH and bilirubin elevation (“intramedullary destruction”) | Frequent: |
| Rare: isolated thrombocytopenia and neutropenia, pancytopenia | Classic: combined sclerosis of the spinal cord | Debatable: abdominal pain, dyspepsia, nausea, vomiting, diarrhea, disturbances in intestinal functioning | Tiredness, loss of appetite |
| Very rare: hemolytic anemia, thrombotic microangiopathy (presence of schistocytes) | Rare: cerebellar syndromes affecting the cranial nerves including optic neuritis, optic atrophy, urinary and/or fecal incontinence | Rare: resistant and recurring mucocutaneous ulcers | Under study: atrophy of the vaginal mucosa and chronic vaginal and urinary infections (especially mycosis), hypotertility and repeated miscarriages, venous thromboembolic disease, angina (hyperhomocysteinemia) |
levels increased significantly in patients receiving oral vita-
and then weekly [49]. In this analysis, serum vitamin B12
with a dose between 1,000 and 2,000
Group evidence-based analysis by the
cobalamin with intramuscular cobalamin therapy [17,40]. An
spective randomized controlled studies comparing oral
This data is in accordance with the results of the two pro-
spective randomized controlled studies comparing oral
cobalamin with intramuscular cobalamin therapy [17,40]. An
evidence-based analysis by the Vitamin B12 Cochrane
Group also supports the efficacy of oral cobalamin therapy,
with a dose between 1,000 and 2,000 µg given initially daily
and then weekly [49]. In this analysis, serum vitamin B12
levels increased significantly in patients receiving oral vita-
im B12 and both groups of patients (receiving oral and in-
tramuscular treatment) had neurological improvement.

In a randomized, parallel-group, double-blind, dose-
finding trial, Eussen et al. showed that the lowest dose of
oral cyanocobalamin required to normalize mild cobalamin
deficiency is more than 200 times the recommended dietary
allowance of approximately 3 µg daily (i.e. >500 µg per day)
[50]. The procedure for oral cobalamin treatment has, how-
ever, not been completely validated yet in real life, particu-
larly the long-term efficacy [51]. To date, as several authors
suggest, oral cobalamin therapy remains one of “medicine’s
best kept secrets” [52]. Nevertheless, the following can be
proposed: ongoing supplementation until associated disor-
ders is corrected (e.g. by halting the ingestion of the offend-
ing medication or exogenosis, or by treating H. pylori infec-
tion or pancreatic exocrine failure), lifelong administration
or, when applicable, sequential administration [4,14].

ACKNOWLEDGMENTS

We are indebted to Professor Marc Imler and Jean-Louis
Schlienger who initiated this work and to Helen Fothergill

Table 4. Experience of oral Cobalamin Therapy for Food-Cobalamin Malabsorption in the University Hospital of Strasbourg,
France

| Study Characteristics (Number of Patients) | Therapeutic Modalities | Results | Ref. |
|------------------------------------------|------------------------|---------|-----|
| Open prospective study of well-
documented vitamin B12 defi-
ciency related to food-cobalamin malabsorption (n = 10) | Oral crystalline cyanocobalamin: 650 µg per day, during at least 3 months | – Normalization of serum vitamin B12 levels in 80% of the patients
– Significant increase of hemoglobin (Hb) levels (mean of 1.9 g/dL) and decrease of mean erythrocyte cell volume (ECV) (mean of 7.8 fL)
– Improvement of clinical abnormalities in 20% of the patients
– No adverse effect | [42] |
| Open prospective study of low vitamin B12 levels not related to pernicious anemia (n = 20) | Oral crystalline cyanocobalamin: between 1000 µg per day during at least 1 week | – Normalization of serum vitamin B12 levels in 85% of the patients
– No adverse-effect | [43] |
| Open prospective study of well-
documented vitamin B12 defi-
ciency related to food-cobalamin malabsorption (n = 30) | Oral crystalline cyanocobalamin: between 1000 and 250 µg per day, during 1 month | – Normalization of serum vitamin B12 levels in 87% of the patients
– Significant increase of Hb levels (mean of 0.6 g/dL) and decrease of ECV (mean of 3 fL); normalization of Hb levels and ECV in 54% and 100% of the patients, respectively
– Dose effect - effectiveness dose of vitamin B12 ≥500 µg per day
– No adverse-effect | [41] |
| Open prospective study of low vitamin B12 levels not related to pernicious anemia (n = 30) | Oral crystalline cyanocobalamin: between 1000 and 125 µg per day during at least 1 week | – Normalization of serum vitamin B12 levels in all patients with at least a dose of vitamin ≥250 µg per day
– Dose effect - effectiveness dose of vitamin B12 ≥500 µg per day
– No adverse-effect | [44] |
| Open prospective study of low vitamin B12 levels related to pernicious anemia (n = 10) | Oral crystalline cyanocobalamin: 1000 µg per day, during at least 3 months | – Significant increase of serum vitamin B12 levels in 90% of the patients (mean of 117.4 pg/mL)
– Significant increase of Hb levels (mean of 2.45 g/dL) and decrease of ECV (mean of 10.4 fL)
– Improvement of clinical abnormalities in 30% of the patients | [48] |
Update of Food-Cobalamin Malabsorption and Oral Cobalamin Therapy

who kindly edited the English of this text. The research on cobalamin deficiency was supported by a grant of the Fondation de France (Prix Robert et Jacqueline Zittoun 2004).

REFERENCES

[1] Matthews JH. Cobalamin and folate deficiency in the elderly. Baillière’s Clin Haematol 1995; 54: 245-53.
[2] Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood 1990; 76: 871-81.
[3] Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol 2006; 5: 949-60.
[4] Carmel R. Current concepts in cobalamin deficiency. Ann Rev Med 2000; 51: 357-75.
[5] Snow C. Laboratory diagnosis of vitamin B12 and folate deficiency. A guide for the primary care physician. Arch Intern Med 1999; 159: 1289-98.
[6] Zittoun J, Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. Sem Haematol 1999; 36: 35-46.
[7] Klee GG. Cobalamin and folate evaluation: measurements of methylmalonic acid and homocysteine vs vitamin B12 and folate. Clin Chem 2000; 46: 1277-83.
[8] Andrès E, Perrin AE, Kraemer JP, et al. Anémies par carence en vitamine B12 chez le sujet âgé de plus de 75 ans: nouveaux concepts. A propos de 20 observations. Rev Med Interne 2000; 21: 946-55.
[9] Markle HV. Cobalamin. Crit Rev Clin Lab Sci 1996; 33: 247-356.
[10] Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60: 2-11.
[11] Pautas E, Chépin P, De Jaeger C, Godeau P. Carence en vitamine B12 chez le sujet âgé. Presse Med 1999; 28: 1767-70.
[12] van Asselt DZ, Blom HJ, Zuiderent R, et al. Clinical significance of low cobalamin levels in older hospital patients. Neth J Med 2000; 57: 41-9.
[13] Nicolas JP, Guéant JL. Absorption, distribution et exécration de la vitamine B12. Ann Gastroenterol Hepatol 1994; 30: 270-82.
[14] Andrès E, Affenberger S, Vinzio S, et al. Food-cobalamin malabsorption in elderly patients: clinical manifestations and treatment. Rev Med Interne 2003; 36: 1268-72.
[15] Loukili N, Noel E, Blaison G, et al. Données actuelles sur la maladie de Biermer. A propos d’une étude rétrospective de 49 patients. Rev Med Interne 2004; 25: 556-61.
[16] Toh BH, van Driel IR, Gleeson PA. Pernicious anaemia. N Engl J Med 1997; 337: 1441-8.
[17] Fruhli RK, Telferi A. Pernicious anaemia revisited. Mayo Clin Proc 1994; 69: 144-50.
[18] Carmel R. Malabsorption of food-cobalamin. Baillière’s Clin Haematol 1995; 8: 639-55.
[19] Andrès E, Noel E, Kaltenbach G, et al. Carences en vitamine B12 avec test de Schilling normal ou syndrome de non-dissociation de la vitamine B12 de ses protéines porteuses chez le sujet âgé. Étude de 60 patients. Rev Med Interne 2003; 24: 218-23.
[20] Carmel R, Aurangzeb I, Ojan D. Associations of food-cobalamin malabsorption with ethnic origin, age, Helicobacter pylori infection, and serum markers of gastritis. Am J Gastroenterol 2001; 96: 63-70.
[21] Kaptan K, Beyan C, Ural AU, et al. Helicobacter pylori - Is it a novel causative agent in Vitamin B12 deficiency? Arch Intern Med 2000; 160: 1349-53.
[22] Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000; 30: 29-33.
[23] Andrès E, Noel E, Ben Abdelghani M. Vitamin B12 deficiency associated with chronic acid suppression therapy. Ann Pharmacother 2003; 37: 1730.
[24] Termannini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998; 104: 422-30.
[25] Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98: 4-19.
[26] Bauman WA, Shaw S, Javatillée E, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000; 23: 1277-31.
[27] Andrès E, Noel E, Goichot B. Metformin-associated vitamin B12 deficiency. Arch Intern Med 2002; 162: 2251-2.
[28] Liu KW, Dai LK, Jean W. Metformin-related vitamin B12 deficiency. Age Aging 2006; 35: 200-1.
[29] Andrès E, Goichot B, Perrin AE, Vinzio S, Demangeat C, Schlen-ger JL. Sjögren’s syndrome: a potential new cause of mild cobalamin deficiency. Rheumatology (Oxford) 2001; 40: 1196-7.
[30] Dharmarajan TS, Adiga GU, Norkus EP. Vitamin B12 deficiency. Recognizing subtle symptoms in older adults. Geriatrics 2003; 58: 30-8.
[31] Andrès E, Affenberger S, Zimmer J, et al. Current hematological findings in cobalamin deficiency. A study of 201 consecutive patients with documented cobalamin deficiency. Clin Lab Haematol 2006; 28: 50-6.
[32] Carmel R, Sarrail M. Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies. Curr Hematol Rep 2006; 5: 23-33.
[33] Abyad A. Prevalence of vitamin B12 deficiency among demented patients and cognitive recovery with cobalamin replacement. J Nutr Health Aging 2002; 6: 254-60.
[34] Andrès E, Kaltenbach G. Prevalence of vitamin B12 deficiency among demented patients and cognitive recovery with cobalamin replacement. J Nutr Health Aging 2003; 7: 309-10.
[35] Elia M. Oral or parenteral therapy for B12 deficiency. Lancet 1998; 352: 1721-2.
[36] Bolaman Z, Kadikoşy Y, Yusakosoglu I, Barutca S, Senturk T. Oral versus intramuscular cobalamin treatment in megaloblastic anaemia: a single-center, prospective, randomized, open-label study. Clin Ther 2003; 25: 3124-34.
[37] Andrès E, Kaltenbach G, Noel E, et al. Efficacy of short-term oral cobalamin therapy for the treatment of cobalamin deficiencies related to food-cobalamin malabsorption. A study of 30 patients. Clin Lab Haematol 2003; 25: 161-6.
[38] Andrès E, Kurtz JE, Perrin AE, Maloisel F, Demangeat C, Goiicoth B, et al. Oral cobalamin therapy for the treatment of patients with food-cobalamin malabsorption. Am J Med 2001; 111: 126-9.
[39] Kaltenbach G, Noblet-Dick M, Andre E, et al. Réponse précoce au traitement oral par vitamine B12 chez des sujets âgés hypovitaminés. Ann Med Interne (Paris) 2003; 154: 91-5.
[40] Andrès E, Kaltenbach G, Noblet-Dick M, et al. Hematological response to short-term oral cyanocobalamin therapy for the treatment of cobalamin deficiencies in elderly patients. J Nutr Health Aging 2006; 10: 3-6.
[41] Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Pract 2006; 23: 279-85.
[42] Sölt WB, Merkus FW, Van Deventer SJ, Tytgat GN. Normalization of plasma vitamin B12 concentration by intranasal hydroxocobalamin in vitamin B12-deficient patients. Gastroenterology 1997; 113: 430-3.
[43] van Asselt DZ, Merkus FW, Russel FG, Hoefnagels WH. Nasal absorption of hydroxocobalamin in healthy elderly adults. Br J Clin Pharmacol 1998; 45: 83-6.
[44] Andrès E, Loukili NH, Noel E, et al. Oral cobalamin (daily dose of 10 000 µg) therapy for the treatment of patients with pernicious anemia. An open label study of 10 patients. Curr Ther Research 2005; 66: 13-22.
[45] Vidal-Alaball J, Butler CC, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev 2005; 20: CD004655.
Eussen SJ, de Groot LC, Clarke R, et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Med 2005; 165: 1167-72.

Roth M, Orija I. Oral vitamin B12 therapy in vitamin B12 deficiency. Am J Med 2004; 116: 358.

Graham ID, Jette N, Tetroe J, Robinson N, Milne S, Mitchell SL. Oral cobalamin remains medicine's best kept secret. Arch Gerontol Geriatr 2007; 44: 49-59.